Quinapril Hydrochloride Articles
Generics firms taking more aggressive stance, says report
15 August 2005
Good and bad news for Pfizer on patents
4 April 2005
Mylan gets OK for generic Accupril in USA
10 January 2005
Barr and Pfizer win patent litigations
12 July 2004
US generics approvals for Teva and B&L
16 June 2003
Teva gets tentative US approval for quinapril
18 February 2002
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
Sanofi:Warner Lambert Link: No Comment
21 March 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
W-L's Diabetes Drug Backed For US Approval
23 December 1996
Warner-Lambert Plans JV With Sankyo For Troglitazone And Other Prods
30 September 1996
Quinapril For Ischemic Heart Disease
19 August 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Analysts' Eyes On Warner-Lambert
20 February 1995
End Of Year Encouraging For US Companies
6 February 1995
WARNER-LAMBERT POSTS 1st QTR GROWTH
25 April 1994
PARKE-DAVIS ACE INHIBITOR OFFER
14 February 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
ACCUPRIL APPROVED FOR CHF INDICATION
15 November 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
ALL HOPES ON COGNEX AT WARNER-LAMBERT
26 April 1993
FDA PANEL ADVISES ON ACE INHIBITOR DRUGS
1 March 1993
US RESULTS 3RD QTR
2 November 1992
WARNER-LAMBERT EARNINGS FORECAST
29 June 1992
WARNER-LAMBERT'S VIEW TO THE FUTURE
27 April 1992
OPTIMISTIC ANALYSIS OF WARNER-LAMBERT
13 April 1992
EC PLENARY SESSION DECISIONS
6 January 1992
Showing 1-41 of 41 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
